Scott Sieckert

VP, Finance at Tarsus Pharmaceuticals

Speaker

Scott has more than 15 years of finance and operations experience in the life science industry. His expertise includes building finance organizations to support successful product launches and leading global accounting operations, tax, and financial reporting teams. Prior to joining Tarsus, Scott served in finance roles of increasing responsibility across several Biotech/Biopharma organizations. He most recently served as the Global Corporate Controller for Global Blood Therapeutics, Inc. (GBT), where he led in accounting, including working with the acquisition and integration efforts with Pfizer who acquired GBT in October 2022. Prior to his time at GBT, Scott was the Controller at MyoKardia, Inc. where he led efforts to support the commercialization of Mavacamten, the company’s first product, and built the accounting function globally. Before Myokardia, Scott was the Controller at Adamas Pharmaceuticals where he supported the finance team with the launch of its first product, Gocovori®. Scott began his career in finance at Ernst & Young (EY) in the external audit practice where he served life science clients in the San Francisco Bay Area in addition to a 3-year secondment in Basel, Switzerland. Scott holds an MBA from the University of the Pacific with a concentration in Finance/Accounting, a BS in Genetics from University California, Davis, and is a certified public accountant (active) in the state of CA.